RET and lung carcinoma: A brisk and durable ongoing response to LOXO-292 was achieved in a patient with a RET fusion-positive lung cancer who had notable disease progression while receiving a prior multikinase inhibitor and multiple prior stereotactic radiosurgery treatments.